Dr. Paolo Tarantino is a breast medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, both located in Boston, Massachusetts, as well as a clinical researcher at the European ...

Katrina Columna, FNP, of Memorial Sloan Kettering Cancer Center, blends deep clinical expertise with steady compassion across GI and GYN oncology and early-phase clinical trials. Bradford Aldrich, RN, ...

FDA authorized Tregzi for adults with acute leukemia, MDS, and other hematologic malignancies receiving closely matched donor ...

A Department of Defense–funded initiative targets underrepresented kidney cancer populations to improve clinical trial participation and address persistent disparities in access to novel therapies.

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Susan Rux, RN, of Fox Chase Cancer Center, leads federally funded research to expand clinical trial access for underrepresented kidney cancer patients while mentoring the next generation of oncology ...

Learn why comprehensive biomarker testing is essential before starting any lung cancer treatment. Hear from patients and ...

Inclusive leadership is demonstrated through consistent respect, psychological safety, and communication that makes patients ...

Oncology physical therapist Dr. Leslie Waltke demonstrates calf raises, a simple at-home exercise to help rebuild lower body ...

For Scerbo, the answer traces back to a single patient, a boy she met during her pediatric rotation who was being treated for ...

A UF Health oncologist answers the most common questions about cell therapy, from who qualifies to how it differs from ...

Initial remission underscored a persistent survivorship burden, characterized by mistrust of the body and concurrent gratitude, fear, and anxiety despite family-wide relief. Recurrence catalyzed ...